Immunotherapy has transformed cancer care, offering a way to harness the body’s own immune system to fight tumors. But even with these advances, many patients still don’t respond. One major barrier to ...
The company reiterated that the ASPEN-Breast Phase II trial is "on track to dose its first patient this quarter," with interim data expected in Q3 2026. ALX2004 initial safety data is expected in the ...
First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s ...
Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide. Recent advancements in immunotherapy have demonstrated the potential of targeting immune checkpoints and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company raised hundreds of ...
A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results